title: Methotrexate for the treatment of refractory Crohn's disease.
abstract: BACKGROUND
  Previous studies suggested that methotrexate has beneficial effects in patients with Crohn's disease. We report our experience with this agent in patients with chronic active Crohn's disease who previously failed to improve with conventional treatment, including azathioprine in most cases.
  
  
  METHODS
  Between June 1988 and June 1992, 39 patients with refractory Crohn's disease were treated with methotrexate. In patients with active disease, clinical remission was defined by a Harvey-Bradshaw index of less than 4. For patients also taking corticosteroids, the dates of remission and complete steroid withdrawal were recorded. For patients who achieved clinical remission, and those in clinical remission when methotrexate was started, the relapse rate on methotrexate therapy was noted.
  
  
  RESULTS
  In the 37 patients with active disease at methotrexate initiation, the probability of remission was 72% at 3 months. The probability of remission and steroid withdrawal was 42% at 12 months. In patients on clinical remission, the probability of relapse on methotrexate was 58% at 12 months. Twenty-two patients experienced side-effects, but these only warranted methotrexate discontinuation in four cases.
  
  
  CONCLUSIONS
  Methotrexate appears effective in most patients with refractory Crohn's disease and its short-term toxicity is acceptable, but the long-term benefit seems more limited.
authors.affiliation: Department of Gastroenterology, Hôpital Saint-Louis, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Lémann
authors.forename: C
authors.initials: C
authors.lastname: Chamiot-Prieur
authors.forename: B
authors.initials: B
authors.lastname: Mesnard
authors.forename: M
authors.initials: M
authors.lastname: Halphen
authors.forename: B
authors.initials: B
authors.lastname: Messing
authors.forename: J C
authors.initials: JC
authors.lastname: Rambaud
authors.forename: J P
authors.initials: JP
authors.lastname: Gendre
authors.forename: J F
authors.initials: JF
authors.lastname: Colombel
authors.forename: R
authors.initials: R
authors.lastname: Modigliani
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000963:Antimetabolites / Q000008:administration & dosage / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence
chemical_list: D000305:Adrenal Cortex Hormones; D000963:Antimetabolites; D008727:Methotrexate